Objective: To evaluate the etiology and management of delayed epistaxis after endoscopic surgery.
Method: To retrospectively analyze the clinical data of 11 cases for epistaxis after nasal endoscopic surgery. To compare their precipitating factors, their surgical approach, time and site of bleeding and management in order to find the intrinsic rules.
Result: The precipitating factors, bleeding sites and treatments varied among patients.
Conclusion: Delayed epistaxis after endoscopic surgery can not be neglected. There may be some precipitating factors. The surgical approach may be related to the bleeding site. It is better to treat the epistaxis using the endoscope to explore the bleeding site and to give corresponding intervention.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Palato-Antral Involvement of a Primary Extracranial Sinonasal Meningioma.
Sultan Qaboos Univ Med J
November 2024
Department of ENT, GSL Medical College, Rajahmundry, India.
Article Synopsis
- - Primary extracranial sinonasal meningiomas are extremely rare tumors in the head and neck area, with limited cases documented, particularly involving the palato-antral region.
- - A 45-year-old male experienced nasal issues like frequent bleeding and blockage for 8 months, leading to a diagnosis of a meningioma that affected his palate; he underwent successful surgery using both intraoral and endoscopic methods.
- - Post-surgery, the patient healed well and has shown no signs of recurrence for over two years; however, accurate diagnosis requires specific immunohistochemistry tests, and complete surgical removal is essential to prevent any recurrence or complications.
Fanconi anemia (FA) is a rare inherited disorder characterized by congenital abnormalities, progressive bone marrow failure, and a predisposition to malignancies. Detecting FA can be challenging, as it involves identifying increased chromosomal sensitivity to DNA cross-linking agents and detecting causative genetic variants via genome sequencing. We report two cases of siblings with FA, both confirmed to have the FANCD2 variant through whole-exome sequencing (WES).
View Article and Find Full Text PDFA case report of acute myocardial infarction with hereditary hemorrhagic telangiectasia.
J Cardiothorac Surg
October 2024
Department of Cardiology, Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde, 067000, Hebei, China.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by epistaxis, gastrointestinal bleeding, iron deficiency anemia, and arteriovenous malformations (AVMs) affecting the lungs, liver, and brain. Owing to its rarity and diagnostic challenges, early identification is often elusive. Underdiagnosis and prolonged diagnostic delays are prevalent.
View Article and Find Full Text PDFAmelanotic Melanoma: A Rare Sinonasal Malignancy.
Indian J Otolaryngol Head Neck Surg
October 2024
Department of ENT and Head & Neck Surgery, Kasturba Medical College, Mangalore Manipal Academy of Higher Education, Manipal, India.
Article Synopsis
- Mucosal melanomas are rare, aggressive tumors from melanocytes in mucosal tissues, making up less than 1% of sinonasal cancers; their diagnosis is often delayed due to vague symptoms.
- A case study of a 75-year-old woman highlights the challenges of diagnosing amelanotic sinonasal melanoma, complicated by significant bleeding during biopsy, but ultimately resolved through a detailed clinical approach.
- The successful treatment involved surgical removal despite bleeding, followed by chemotherapy and radiotherapy, emphasizing the need for a coordinated, personalized strategy for managing such rare cancers based on their specific characteristics.
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.
Lancet Microbe
November 2024
Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Article Synopsis
- rVSVΔG-ZEBOV-GP is a vaccine that helps protect people from the Ebola virus and is the first one to be officially approved for this purpose.
- This study wanted to see how well a booster shot given 18 months after the first vaccine dose helped keep the immune response strong for a longer time.
- Healthy adults who might be at risk of exposure to Ebola participated in the trial, and the results measured their antibody levels 36 months after the first vaccination to compare those who got the booster with those who did not.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!